Study reveals level of magnesium sulfate to prevent cerebral palsy in preterm infants

A new study suggests that to optimize neuroprotection and prevent cerebral palsy in extremely preterm infants, women should receive magnesium sulfate to obtain a blood level between 3.7 and 4.4 mg/dL at the time of delivery. The study included 636 women who received magnesium sulfate and 1269 who received placebo.

The findings are important because magnesium sulfate is indicated for neuroprotection of preterm fetuses; however, the optimal dosing schedule to prevent is not known.

"Women have traditionally received a standard dose of magnesium sulfate to prevent cerebral palsy in the extremely preterm fetus, but this study is the first to use pharmacokinetic modeling to suggest a therapeutic target maternal serum level we should aim for," said Dr. Kathleen Brookfield, lead author of the Journal of Clinical Pharmacology study. "The dose of can now be tailored depending on and the clinical situation to achieve this target."


Explore further

Effect of magnesium sulfate during pregnancy on very preterm infants

More information: Kathleen F. Brookfield et al, Optimization of Maternal Magnesium Sulfate Administration for Fetal Neuroprotection: Application of a Prospectively Constructed Pharmacokinetic Model to the BEAM Cohort, The Journal of Clinical Pharmacology (2017). DOI: 10.1002/jcph.941
Provided by Wiley
Citation: Study reveals level of magnesium sulfate to prevent cerebral palsy in preterm infants (2017, June 7) retrieved 17 October 2019 from https://medicalxpress.com/news/2017-06-reveals-magnesium-sulfate-cerebral-palsy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
1 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more